Incidence and relative risk of metachronous second primary cancers for 16 cancer sites, Osaka, Japan, 2000-2015: Population-based analysis.
alcohol-related cancer
cumulative risk
epidemiology
incidence rate
multiple primary cancers
smoking-related cancer
standardized incidence ratio
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
01
11
2021
received:
25
08
2021
accepted:
01
11
2021
pubmed:
1
12
2021
medline:
16
3
2022
entrez:
30
11
2021
Statut:
ppublish
Résumé
An increasing number of cancer survivors have developed multiple primaries. This study aims to describe the incidence and risk patterns of metachronous second primary cancers (SPCs) in Osaka, Japan. Data were obtained from the Osaka Cancer Registry, a population-based database of all cancers diagnosed in Osaka. The study subjects were individuals who were first diagnosed with invasive cancers in 16 major cancer sites during 2000-2014, aged 15-79 years, survived at least 3 months, and were followed up for 10 years. We measured incidence rates, cumulative risks, and standardized incidence ratios (SIRs: with the Osaka general population as the referent) of developing SPCs during 3 months to 10 years after the first diagnosis. During 2000-2015, among 418,791 cancer survivors, 24,368 (5.8%) developed SPCs within 10 years of first diagnosis. Males had higher incidence rates than females except among young-onset survivors (aged 15-39 years). 10-year cumulative risks among survivors aged 70-79 years (the most dominant age group) were 24.0% (male) and 11.8% (female). 10-year SIRs were 1.38 (95% CI, 1.36-1.40; male) and 1.44 (95% CI, 1.41-1.48; female) with higher estimates among younger survivors in both sexes. Strong bidirectional associations were observed between oral/pharyngeal, esophageal, and laryngeal cancers. Survivors of any smoking-related cancers had elevated SIRs of developing smoking-related SPCs. Similar results were observed for alcohol-related cancers. Cancer survivors are at excess risk of developing SPCs compared to the general population. Continued surveillance is warranted to inform survivorship care through risk-based long-term care planning and lifestyle-changing efforts to prevent new cancers.
Sections du résumé
BACKGROUND
An increasing number of cancer survivors have developed multiple primaries. This study aims to describe the incidence and risk patterns of metachronous second primary cancers (SPCs) in Osaka, Japan.
METHODS
Data were obtained from the Osaka Cancer Registry, a population-based database of all cancers diagnosed in Osaka. The study subjects were individuals who were first diagnosed with invasive cancers in 16 major cancer sites during 2000-2014, aged 15-79 years, survived at least 3 months, and were followed up for 10 years. We measured incidence rates, cumulative risks, and standardized incidence ratios (SIRs: with the Osaka general population as the referent) of developing SPCs during 3 months to 10 years after the first diagnosis.
RESULTS
During 2000-2015, among 418,791 cancer survivors, 24,368 (5.8%) developed SPCs within 10 years of first diagnosis. Males had higher incidence rates than females except among young-onset survivors (aged 15-39 years). 10-year cumulative risks among survivors aged 70-79 years (the most dominant age group) were 24.0% (male) and 11.8% (female). 10-year SIRs were 1.38 (95% CI, 1.36-1.40; male) and 1.44 (95% CI, 1.41-1.48; female) with higher estimates among younger survivors in both sexes. Strong bidirectional associations were observed between oral/pharyngeal, esophageal, and laryngeal cancers. Survivors of any smoking-related cancers had elevated SIRs of developing smoking-related SPCs. Similar results were observed for alcohol-related cancers.
CONCLUSIONS
Cancer survivors are at excess risk of developing SPCs compared to the general population. Continued surveillance is warranted to inform survivorship care through risk-based long-term care planning and lifestyle-changing efforts to prevent new cancers.
Identifiants
pubmed: 34845852
doi: 10.1002/cam4.4457
pmc: PMC8729047
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
507-519Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Lett. 2015 Dec 1;369(1):152-66
pubmed: 26319898
J Natl Cancer Inst. 2001 May 2;93(9):705-9
pubmed: 11333293
PLoS One. 2017 Jun 14;12(6):e0179387
pubmed: 28614405
Nat Rev Clin Oncol. 2013 May;10(5):289-301
pubmed: 23529000
Cancer. 2012 Jun 15;118(12):3153-64
pubmed: 22271645
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1330-5
pubmed: 22669949
BMC Public Health. 2012 Sep 14;12:784
pubmed: 22974404
Prev Med. 2004 Sep;39(3):449-57
pubmed: 15313083
J Cancer Surviv. 2016 Feb;10(1):142-52
pubmed: 26159159
JAMA Oncol. 2019 Mar 1;5(3):318-325
pubmed: 30570657
ESMO Open. 2017 May 2;2(2):e000172
pubmed: 28761745
BMC Cancer. 2014 Feb 15;14:94
pubmed: 24528929
PLoS One. 2009 Nov 11;4(11):e7695
pubmed: 19907646
Public Health. 2008 Nov;122(11):1144-51
pubmed: 18793784
BMC Cancer. 2011 Feb 23;11:83
pubmed: 21342533
Ann Surg Oncol. 2007 Oct;14(10):2759-65
pubmed: 17593332
Cancer Med. 2022 Jan;11(2):507-519
pubmed: 34845852
Int J Cancer. 2015 Nov 1;137(9):2114-23
pubmed: 25904109
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
JAMA Netw Open. 2020 Jul 1;3(7):e209072
pubmed: 32614423
Cancer Sci. 2014 Jul;105(7):890-6
pubmed: 24814518
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):963-970
pubmed: 28096199
Jpn J Cancer Res. 1994 Apr;85(4):339-45
pubmed: 8200845
Cancer Causes Control. 2009 Oct;20(8):1431-40
pubmed: 19526319
Cancer. 1995 Aug 1;76(3):442-52
pubmed: 8625126
BMC Cancer. 2020 Jan 21;20(1):51
pubmed: 31964352
JAMA Intern Med. 2020 Nov 1;180(11):1436-1447
pubmed: 32667668
PLoS One. 2017 Apr 24;12(4):e0176087
pubmed: 28437472
JAMA. 2020 Dec 22;324(24):2521-2535
pubmed: 33351041
Cancer Sci. 2012 Jun;103(6):1111-20
pubmed: 22364479
Nat Rev Urol. 2014 Apr;11(4):197-212
pubmed: 24595118
Cancer. 2016 Jan 1;122(1):116-23
pubmed: 26441212
Eur J Cancer Prev. 2015 Mar;24(2):150-4
pubmed: 25397586